| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Snider William | Director | C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD, HOLLISTON | /s/ William Snider | 18 Mar 2026 | 0001340831 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | HBIO | Common Stock | Purchase | +12,525 | +114% | $4.99* | 23,525 | 16 Mar 2026 | Direct | F1, F3, F5 | |
| transaction | HBIO | Common Stock | Purchase | +8,475 | +36% | $4.85* | 32,000 | 17 Mar 2026 | Direct | F2, F4, F5 |
| Id | Content |
|---|---|
| F1 | The price in Column 4 is a weighted average price. These shares were purchased in multiple transactions, and the prices actually paid ranged from $4.85 to $5.00, inclusive. The reporting person has provided to the Issuer, and will provide to any security holder of the Issuer, or the Securities and Exchange Commission ("SEC") staff, upon request, information regarding the number of shares purchased at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price. |
| F2 | The price in Column 4 is a weighted average price. These shares were purchased in multiple transactions, and the prices actually paid ranged from $4.80 to $4.95, inclusive. The reporting person has provided to the Issuer, and will provide to any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price. |
| F3 | Includes (a) 12,525 shares of common stock purchased on March 16, 2026, and (b) 11,000 restricted stock units that fully vest on December 17, 2026. |
| F4 | Includes (a) 12,525 shares of common stock purchased on March 16, 2026, (b) 8,475 shares of common stock purchased on March 17, 2026, and (c) 11,000 restricted stock units that fully vest on December 17, 2026. |
| F5 | On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnotes 3(b) and 4(c) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026. |